New therapies for chronic hepatitis B infection

Liver International

Volumn 26, Issue SUPPL. 2, 2006, Pages 30-37

  Chang, T T ^a   Jia, Jidong D ^b   Omata, Masao ^c   Yoon, S K ^d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO   (Japan)

^d The Catholic University of Korea   (South Korea)

Author keywords

Adefovir; Chronic hepatitis B virus infection; Clevudine; Entecavir; Peginterferon 2a; Telbivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CLEVUDINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LDT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ASIA; CHINESE; CLINICAL TRIAL; COMORBIDITY; DATA ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; EXPERIENCE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RECEPTOR BINDING; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33750707232     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01373.x     Document Type: Review

References (44)

1. World Health Organization. Hepatitis B -Surveillance and control. Available at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/ en/index1.html. Accessed June 21, 2006.
2. Lin S M, Tai D I, Chien R N, Sheen I S, Chu C M, Liaw Y F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepatol 2004; 11: 349-57.
3. van Zonneveld M, Honkoop P, Hansen B E, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
4. Lin S M, Yu M L, Lee C M, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2006; in press.
5. Goodman Z, Dhillon A P, Wu P C, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 1999; 30 (Suppl. 1): 59.
6. Dienstag J L, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
7. Liaw Y F, Sung J J Y, on behalf of the CALM Study Group et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
8. Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
9. Marcellin P, Chang T T, Lim S G, et al, For the Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
10. Lai C L, Ratziu V, Yuen M F, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
11. Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis 2005; 25 (Suppl. 1): 9-19.
12. Liaw Y F. The current management of HBV drug resistance. J Clin Virol 2005; 34 (Suppl. 1): S143-6.
13. Chang T T, Gish R G, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
14. Lai C L, Shouvald D, Lok A S, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
15. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
16. Lau G K, Piratvisuth T, Luo K X, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
17. Marcellin P, Lau G K, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
18. Wilber R, Brett-Smith H, Zhu J, et al. Entecavir (ETV) vs. adefovir (ADV): HBV DNA reduction in chronically infected HBeAg+nucleoside-naive adults in a 12-week viral kinetics study, Presented at the NIH Management of Hepatitis B Conference, April 6, 2006, Bethesda, MD.
19. Lai C L, Gane E, Liaw Y F, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III GLOBE trial, abstract LB1. Hepatology 2005; 42: 748A.
20. Marcellin P, Mommeja-Marin H, Sacks S L, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-8.
21. Lee H S, Chung Y H, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 982-8.
22. Colonno R J, Genovesi E V, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184: 1236-45.
23. de Man R A, Wolters L M, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34: 578-82.
24. Ono-Nita S K, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103: 1635-40.
25. Chang T, Chao Y-C, Sollano J. Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg+chronic hepatitis B (CHB) patients (study ETV-022). Presented at the Shanghai-Hong Kong International Liver Congress, March 25-28, 2006, Shanghai, China.
26. Shouval D, Akarca U, Hatzis G. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg- chronic hepatitis B patients (study ETV-027). Program and abstracts of the 41st Annual Meeting of the European Association for the Study of the Liver, April 26-30, 2006, Vienna, Austria.
27. Yurdaydin C, Sollano J. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg+chronic hepatitis B patients (ETV-026). Presented at the 41st Annual Meeting of the European Association for the Study of the Liver; April 26-30, 2006, Vienna, Austria.
28. Colonno R J, Rose R E, Levine S M, et al. Entecavir (ETV) resistance is not observed in nucleoside-naive subjects and is observed infrequently by week 48 in lamivudine-refactory subjects with chronic HBV infection, abstract 478. J Hepatol 2005; 42 (Suppl. 2): 573A.
29. Yao G B, Chen C W, Lu W L, et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B: Results of the phase 3 study ETV-023 in nucleoside-naive patients. Program and abstracts of the 2006 Shanghai-Hong Kong International Liver Congress; March 25-28, 2006, Shanghai, China, abstract 174.
30. Yao G B, Ren H, Wang B E, Zhou X Q. Randomized, placebo controlled phase II study of entecavir in patient who have failed lamivudine therapy (ETV-056). Chinese Hepatol 2005; 10: 2-4.
31. Lau G K, Piratvisuth T, Thongsawat S, et al. Durability of response to peginterferon alfa-2a (40KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B: 12 month follow-up data from a large, randomized study. Program and abstracts of the 2006 Shanghai-Hong Kong International Liver Congress, March 25-28, 2006, Shanghai, China, abstract 49.
32. Marcellin P, Bonino F, Lau G K, et al. Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2a (40KD) (Pegasys®) monotherapy for HBeAg-negative chronic hepatitis B, abstract 976. Hepatology 2005; 42: 580A.
33. Lai C L, Leung N, Teo E K, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
34. Lim S G, Lai C L, Gane E, et al. The antiviral efficacy of telbivudine is consistent across hepatitis B patient subgroups: Results from the GLOBE study. Shanghai-Hong Kong International Liver Congress, March 25-28, 2006.
35. Buti M, Esteban R. Entecavir, FTC, L-FMAU, LdT and others. J Hepatol 2003; 39 (Suppl. 1): S139-42.
36. Lok A S. New treatment of chronic hepatitis B. Semin Liver Dis 2004; 24 (Suppl. 1): 77-82.
37. Yoo B C, Kim J H, Lee K S, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients. Hepatology 2005; 42: 270A.
38. Yoo B C, Kim J H, Lee K S, et al. Clevudine is highly efficacious in HBeAg(-) chronic hepatitis B patients with a sustained antiviral effect after cessation of therapy. Hepatology 2005; 42: 268A.
39. van Bömmel F, Mauss S, Zollner B, et al. Longterm effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir. Hepatology 2005; 42 (Suppl. 1): 269A.
40. van Bömmel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
41. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001; 358: 718-23.
42. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44: 62-7.
43. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
44. Dore G J, Cooper D A, Pozniak A L, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92.